万赛维可以治什么？

It is the prodrug of ganciclovir and an active ganciclovir valine ester. After oral administration, it can be rapidly hydrolyzed into ganciclovir by phosphatase in intestinal and liver cells. Its antiviral spectrum and mechanism of action are similar to ganciclovir, but its bioavailability is significantly higher than that of ganciclovir. Its oral bioavailability is 62.4%, which is 10 times that of ganciclovir, while its toxicity is greatly reduced.

So what can Wansaiwei treat?

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients. On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Common side effects: Gastrointestinal disorders: bloating, cholangitis, dyspepsia, dysphagia, hiccups, esophagitis, fecal incontinence, flatulence, gastritis, gastrointestinal disorders, gastrointestinal bleeding, oral ulcers, pancreatitis, tongue disorders. Systemic: ascites, asthenia, bacterial, fungal and viral infections, bleeding, malaise, mucosal disease, pain, photosensitivity, chills, sepsis. Liver disorders: hepatitis, jaundice. Skin and Appendages: Hair loss, dry skin, increased sweating, urticaria. Central and peripheral nervous system: abnormal dreaming, amnesia, anxiety, ataxia, coma, dry mouth, emotional instability, hyperkinesia syndrome, hypertonia, hyposexuality, myoclonus, nervousness, drowsiness, abnormal thinking, tremor. Musculo-skeletal system: musculoskeletal pain, myasthenic syndromes. Urinary system: hematuria, impotence, renal failure, frequent urination.